is teva a good buy?
In 2015, before the Actavis Generics acquisition, Teva stock was considered a good buy at about $70. Today, shares are sitting at a 52-week high of $20.21 and a 52-week low of $6.07, and the future looks far from promising. In its Q3 report, Teva reported EPS at $0.58, a 14.7% year-over-year slump.